恩替卡韦初治HBeAg阳性慢性乙型肝炎患者HBsAg与HBV DNA变化的相关性分析

The correlation analysis between serum HBsAg and HBV DNA levels of Entecavir in treatment of e antigen positive chronic hepatitis B patients

目的通过检测恩替卡韦初治HBe Ag阳性的慢性乙型肝炎患者的过程中乙肝表面抗原(HBs Ag)与HBV DNA载量,探讨抗病毒治疗过程中HBs Ag与HBV DNA的关系,观察HBs Ag用于评估恩替卡韦抗病毒治疗的效果。方法 125例HBe Ag阳性慢性乙型肝炎患者服用恩替卡韦抗病毒治疗,分别在治疗前、治疗12周、治疗24周、治疗36周定量测定HBs Ag与HBV DNA载量。结果服用恩替卡韦抗病毒治疗36周,HBs Ag水平下降不明显(P=0.146),而HBV DNA水平则持续下降(P<0.05),治疗前两者呈负相关(r=-0.375,P<0.001),应用恩替卡韦抗病毒治疗后二者之间无明显相关性。结论 HBs Ag不能很好地作为恩替卡韦抗病毒治疗过程中的疗效监测指标,在抗病毒治疗过程中评价HBs Ag与HBV DNA二者之间相关性的意义不大。

Objective To investigate the correlation between the HBsAg and HBV DNA levels of Entecavir in treat- ment of e antigen positive chronic hepatitis B patients. Methods One hundred and twenty-five patients were diagnosed as e antigen positive chronic hepatitis B, and the Entecavir was used regularly in the antiviral treatment, the HBsAg and HBV DNA levels were tested before the treatment, 12th weeks, 24th weeks, and 56th weeks after the treatment, respec- tively. Results After the Entecavir antiviral treatment for 36 weeks, HBV DNA level continued to decline （P 〈 0.05）, but HBsAg level didn＇t decline obviously （P =0. 146）. Before the antiviral treatment, HBsAg and HBV DNA showed a negative correlation （ r = - 0. 575, P 〈 0. 001 ）, but after the Entecavir treatment, they had no correlation. Conclusion HBsAg is not good enough to be the curative effect monitoring indicator in the process of Entecavir antivi- ral treatment.